Guideline Recommendations for Holding Systemic Anticoagulation Prior to Colonoscopy with Polypectomy
For colonoscopy with polypectomy (a high-risk procedure), anticoagulation management depends on the specific agent and the patient's thrombotic risk, but in general: warfarin should be stopped 5 days before the procedure with INR checked to ensure <1.5, DOACs should have their last dose 3 days before (5 days for dabigatran if CrCl 30-50 mL/min), and heparin bridging should be avoided in most patients. 1
Risk Stratification
Colonoscopy with polypectomy is classified as a high-risk endoscopic procedure for bleeding 1. This classification is critical because it determines the management approach for anticoagulation.
Warfarin Management
Low Thrombotic Risk Patients
- Stop warfarin 5 days before the procedure (strong recommendation, high quality evidence) 1
- Check INR prior to procedure to ensure <1.5 (strong recommendation, low quality evidence) 1
- Do NOT use heparin bridging - The ACCP 2022 guidelines specifically recommend against heparin bridging for colonoscopy with polypectomy (conditional recommendation, very low certainty of evidence) 2
- Restart warfarin the evening of the procedure with usual daily dose 1
High Thrombotic Risk Patients
High thrombotic risk includes:
- Prosthetic metal heart valve
- AF with mitral stenosis or previous stroke/TIA
- AF with CHADS₂ ≥4 (congestive heart failure, hypertension, age ≥75, diabetes, previous stroke/TIA)
- Recent VTE (within 3 months) or VTE on anticoagulation 1
For these patients:
- Temporarily discontinue warfarin and substitute with LMWH (strong recommendation, low quality evidence) 1
Direct Oral Anticoagulants (DOACs)
Standard Renal Function
- Last dose should be taken 3 days before the procedure (strong recommendation, low quality evidence) 1
Impaired Renal Function
- For dabigatran with CrCl 30-50 mL/min: last dose 5 days prior (strong recommendation, low quality evidence) 1
- Consult hematology for rapidly deteriorating renal function 1
Emerging Evidence
Recent 2026 data suggests DOAC continuation or minimal interruption (morning-of-procedure only) may be safe for polypectomy, particularly with cold snare technique 3, 4. However, current guidelines still recommend the 3-day interruption approach, and this should be followed until prospective trials validate the newer data.
Antiplatelet Agents
Aspirin
- Continue aspirin for all procedures including polypectomy (strong recommendation, low quality evidence) 1
- Exception: ampullectomy (weak recommendation to hold) 1
P2Y12 Receptor Antagonists (Clopidogrel, Prasugrel, Ticagrelor)
Low Thrombotic Risk:
- Stop 7 days before the procedure (strong recommendation, moderate quality evidence) 1
- If on dual antiplatelet therapy (DAPT), continue aspirin 1
- Restart 1-2 days after procedure 1
High Thrombotic Risk (recent coronary stent):
- Continue aspirin
- Liaise with interventional cardiologist about risk/benefit of stopping P2Y12 inhibitor (strong recommendation, high quality evidence) 1
- Consider temporary cessation only if:
- 6-12 months after drug-eluting stent
1 month after bare metal stent 1
Post-Procedure Resumption
Resume anticoagulation 2-3 days after the procedure depending on perceived hemorrhagic and thrombotic risks (strong recommendation, moderate quality evidence) 1
Critical Pitfalls to Avoid
Do not routinely bridge with heparin - This significantly increases bleeding risk without clear thrombotic benefit for most patients 2. The one randomized trial comparing VKA interruption with bridging vs continuation showed 12% bleeding with bridging vs 4.7% with continuation (though not statistically significant) 2
Do not stop aspirin - Unless specifically contraindicated, aspirin continuation is safe and recommended 1
Verify INR before procedure - Even if warfarin was held appropriately, confirm INR <1.5 before proceeding 1
Check renal function for DOAC patients - Dabigatran requires longer interruption with impaired renal function 1
Physician non-adherence increases complications - A 2021 study demonstrated that clinician non-adherence to guidelines was associated with increased delayed post-polypectomy bleeding (adjusted HR 3.54) and serious cardiovascular events (HR 15.63) 5
Special Considerations
Cold snare polypectomy may allow for less aggressive anticoagulation interruption, particularly for polyps ≤10 mm 3, 6. However, this technique-specific approach is not yet incorporated into major society guidelines and should be considered investigational.
Patient counseling is essential - all patients should be advised of increased post-procedure hemorrhage risk compared to those not on anticoagulation (strong recommendation, low quality evidence) 1